FAQ: Provide Immunologic Rationale For IL17-Directed Therapy in PsA, AS, and nr-axSpA 

Join Kyle George, PA-C, in this FAQ Video Module! Kyle provides an immunologic rationale for IL-17 directed therapy in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. He explains how IL-17, particularly IL-17A, drives inflammation and tissue damage in these conditions, and how targeted IL-17 inhibition can reduce inflammation and mitigate symptoms. This approach offers a more precise treatment option for patients with these rheumatic diseases. For more information, visit RhAPP.org.